Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Approved for adults with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and (if RAS wild-type) anti-EGFR therapy; also approved for metastatic gastric/GE junction adenocarcinoma after two or more prior chemotherapy regimens.
1
2
3
4
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Before confirming Trifluridine & Tipiracil as your treatment
About the boxed warning — bone marrow suppression
About the dosing schedule
About day-to-day side effects
About my specific situation
About how we’ll know if it’s working — and what comes next
A practical tip: Because the survival benefit here is measured in a couple of months on average, it’s worth having an early conversation about what matters most to you — more time, comfort, ability to be at home, specific events or milestones — so your care team can help align the treat
Compare trifluridine&tipiracil vs regorafenib for later-line colorectal cancer treatment
Both trifluridine&tipiracil and regorafenib (Stivarga) occupy a similar space — third-line-or-later options for metastatic colorectal cancer after standard chemotherapy has stopped working. Unlike some of our earlier comparisons, these two aren’t generational successors to each other; they’re mechanistically different drugs that are often used sequentially, one after the other.
What they are and how they work
| Trifluridine&tipiracil (Trifluxen) | Regorafenib (Stivarga) | |
| Drug class | Nucleoside analog + thymidine phosphorylase inhibitor | Oral multikinase inhibitor (targets VEGFR, KIT, RET, and others) |
| Mechanism | Gets incorporated into cancer cell DNA, disrupting replication | Blocks multiple signaling pathways involved in tumor growth and blood vessel formation |
| Approved | 2015 (FDA) | 2012 (FDA) |
| Pivotal trial | RECOURSE | CORRECT |
Efficacy comparison
| Trifluxen (RECOURSE) | Regorafenib (CORRECT) | |
| Median OS vs placebo | 7.1 mo vs 5.3 mo | 6.4 mo vs 5.0 mo |
| Median PFS vs placebo | 2.0 mo vs 1.7 mo | 1.9 mo vs 1.7 mo |
Both show a modest but statistically significant survival benefit over placebo/best supportive care — in the same general range. Neither has been shown in head-to-head trials to be clearly superior to the other for overall survival, so the choice often comes down to side effect profile and how it fits the patient’s situation rather than one being definitively “better.”
Dosing schedule — a meaningful practical difference
| Trifluxen | Regorafenib | |
| Form | Oral, twice daily | Oral, once daily |
| Schedule | Days 1–5 and 8–12 of a 28-day cycle (with two rest periods) | Days 1–21 of a 28-day cycle (3 weeks on, 1 week off) |
Some patients find regorafenib’s once-daily, more continuous schedule simpler to follow, while others find Trifluxen’s structure easier because of the built-in rest days each week.
Side effect profiles — quite different
| Trifluxen | Regorafenib | |
| Boxed warning | Severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) | Severe hepatotoxicity (liver injury, including fatal cases) |
| Most distinctive side effect | Low blood counts, infection risk | Hand-foot skin reaction (painful blistering/peeling on palms and soles) |
| Hypertension | Not typical | Common — requires blood pressure monitoring |
| Fatigue | Common | Common |
| GI effects | Nausea, diarrhea, appetite loss | Diarrhea, mucositis |
| Liver monitoring | Less central | Central — LFTs checked regularly, especially early on |
This is often where the decision actually lands: a patient with bone marrow reserve concerns (low baseline counts, prior heavy chemo) might be steered toward regorafenib, while a patient with liver function concerns or at higher risk of hand-foot skin reactions (e.g., from physically demanding work) might be steered toward Trifluxen.
Sequencing — using both
Because they work through different mechanisms and don’t share major toxicities, it’s common for patients to receive both drugs sequentially — one after the other — rather than choosing permanently between them. The order isn’t rigidly defined by guidelines; it often depends on which side effect profile is more manageable given the patient’s current health status at the time each decision point arises.
Bottom line
Neither drug is “later generation” than the other in the way osimertinib succeeded earlier EGFR TKIs — they’re parallel options with similar modest survival benefits but very different toxicity patterns (bone marrow suppression vs liver/skin/blood pressure effects). The conversation with your oncologist often centers on which side-effect profile is more compatible with your current health status, and whether using both, in sequence, makes sense for your overall plan.
Here’s how the dosing and monitoring schedule typically works for Trifluridine & Tipiracil:
The basic schedule — a 28-day cycle
Each treatment cycle is 28 days long, but you’re not taking the medication every day within it:
Then the cycle repeats. So out of each 4-week cycle, you’re actively taking the drug for 10 days total, spread across two 5-day blocks with a 2-day break in between, followed by a longer 16-day break before the next cycle starts.
How each dose is taken
Blood count monitoring — the core safety requirement
Given the boxed warning for bone marrow suppression, blood counts are checked at defined points:
If neutrophil counts, platelet counts, or hemoglobin are too low at any of these checkpoints, your oncologist may delay the start of the next cycle, reduce your dose, or in some cases skip a dose until counts recover.
Other monitoring
What dose adjustments look like in practice
It’s common for the dose to be reduced over the course of treatment if side effects (especially low blood counts) occur — this is a normal part of managing the medication, not a sign that it’s “failing.” Your oncologist will balance maintaining enough dose intensity to be effective against keeping side effects manageable.
A practical note on timing
Because the schedule has specific “on” days that don’t align neatly with calendar weeks, many patients find it helpful to use a pill calendar or phone reminders marking exactly which days are dosing days versus rest days — especially since missing the meal-timing window (within 1 hour after eating) is easy to do without a visual reminder.
This is a sensitive topic where individual factors — your baseline blood counts, kidney function, and how you tolerate the first cycle — will shape how closely your actual schedule follows this template, so your oncology team’s specific instructions for your case should always take priority over general guidance like this.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
Conatact US
